Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-895 Monotherapy and Combination with Navtemadlin in B-Cell Malignancies
NCT02825836Phase 2Active, not recruiting
- Sponsor
- Telios Pharma
- Start
- Aug 2016
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of TL-895 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), sponsored by Telios Pharma. Started Aug 2016; status: active, not recruiting.
02
Drugs
TL-895
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02825836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02825836.